SYROS PHARMACEUTICALS INC's ticker is SYRS and the CUSIP is 87184Q107.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2019 | $17,000 | -5.6% | 1,900 | -5.0% | 0.00% | 0.0% |
| Q1 2019 | $18,000 | -25.0% | 2,000 | -78.5% | 0.00% | 0.0% |
| Q4 2018 | $24,000 | +1100.0% | 9,300 | +4550.0% | 0.00% | – |
| Q3 2018 | $2,000 | -71.4% | 200 | -95.5% | 0.00% | – |
| Q2 2018 | $7,000 | -41.7% | 4,400 | -57.7% | 0.00% | -100.0% |
| Q1 2018 | $12,000 | -88.7% | 10,400 | -54.8% | 0.00% | -75.0% |
| Q4 2017 | $106,000 | – | 23,000 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Ally Bridge Group (NY) LLC | 3,139,895 | $23,486,000 | 4.50% |
| Samsara BioCapital, LLC | 2,189,199 | $14,769,000 | 2.72% |
| Bain Capital Life Sciences Investors, LLC | 5,785,036 | $43,272,000 | 2.45% |
| Omega Fund Management, LLC | 1,562,500 | $11,688,000 | 1.11% |
| Flagship Pioneering Inc. | 2,938,494 | $21,980,000 | 0.35% |
| EcoR1 Capital, LLC | 1,000,000 | $7,480,000 | 0.33% |
| Altium Capital Management LP | 126,702 | $948,000 | 0.26% |
| Nikko Asset Management Americas, Inc. | 5,042,009 | $37,714,000 | 0.18% |
| Artal Group S.A. | 1,025,000 | $7,667,000 | 0.14% |
| Orbimed Advisors | 1,837,500 | $13,745,000 | 0.13% |